Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524782 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT02524782 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 103 participants.
The verdict
NCT02524782, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MEDI4166 in Subjects with Type 2 Diabetes Mellitus (T2D).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI-4166
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2017-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02524782
The ClinicalTrials.gov registry entry for NCT02524782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02524782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02524782 about?
NCT02524782 is a clinical study titled "A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes". A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MEDI4166 in Subjects with Type 2 Diabetes Mellitus (T2D).
What is the current status of trial NCT02524782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2015-10-07. Estimated completion is 2017-04-14.
What interventions are being tested in trial NCT02524782?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI-4166 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02524782?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.